Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
Overview of PerkinElmer Inc.
PerkinElmer Inc. is a globally recognized scientific instrumentation and solutions provider that serves the needs of researchers, clinicians, and scientists in diagnostics, life sciences, and applied markets. With decades of expertise, the company combines state-of-the-art technology with deep industry knowledge to deliver instruments and software that empower precise and early insights in analytical and diagnostic processes.
Core Business Areas
PerkinElmer specializes in multiple business areas, including:
- Diagnostics: Offering advanced tools and methodologies designed to support early disease detection and accurate diagnostics.
- Life Sciences: Providing instrumentation and support services that enhance biological research, drug discovery, and genomic studies.
- Food and Applied Markets: Delivering practical solutions tailored to food safety, environmental monitoring, and quality control.
Business Model and Revenue Generation
The company operates by integrating advanced science and technology with customer-focused services, generating revenue through direct sales of high-performance analytical instruments, licensing of proprietary technologies, and ongoing service contracts. The business model emphasizes long-term customer partnerships and continuous innovation, which are vital in meeting the evolving needs of global research communities.
Market Position and Competitive Landscape
Positioned as a significant player in the scientific instrumentation sector, PerkinElmer competes with other global providers by offering an extensive portfolio of integrated solutions. Its competitive edge stems from its deep technical expertise, robust customer service, and strategic investments in research and development. This approach not only addresses current market challenges but also establishes a broad framework that supports complex research endeavors and regulatory needs.
Technological Innovation and Expertise
At its core, PerkinElmer leverages cutting-edge technologies to enable breakthrough discoveries in science and healthcare. The company continuously evolves its product offerings through innovation in instrument design, software integration, and application-specific solutions. These innovations are a direct result of its commitment to deep market insight and technical expertise, ensuring that its customers benefit from the latest advances in scientific research.
Global Reach and Impact
With a presence in numerous countries worldwide, the company functions as a key enabler in global research efforts. By providing technologies that support both clinical and research applications, PerkinElmer contributes significantly to improving healthcare outcomes and advancing scientific understanding. Its global footprint allows it to serve a diverse array of industries, reinforcing its role as a vital partner in enhancing quality of life through scientific progress.
Commitment to Quality and Customer Partnership
PerkinElmer is dedicated to building strategic partnerships with its customers, offering tailored support and service solutions that meet the specific requirements of complex research and diagnostic projects. This commitment is reflected in its holistic approach to customer engagement, combining product excellence with expert consultancy and robust technical assistance.
Conclusion
In summary, PerkinElmer Inc. encapsulates a sophisticated blend of innovation, market insight, and operational excellence. It remains an influential entity in the scientific and healthcare sectors by consistently providing analytical instrumentation and solutions that empower users to achieve early and accurate results. The company’s ability to integrate advanced technology with practical applications makes it an indispensable partner for global research institutions and healthcare providers alike.
PerkinElmer, a global leader in health innovation, will present at the virtual 2021 Stifel Healthcare Conference on November 16, 2021, at 8:40 a.m. ET. Senior VP and CFO Jamey Mock will discuss the company's strategic priorities. Interested participants can register for the event here. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after.
PerkinElmer reported third quarter 2021 revenue of $1.17 billion, reflecting 21% growth year-over-year, with 12% organic growth. GAAP earnings per share (EPS) from continuing operations fell to $1.11, down from $1.57 in Q3 2020, while adjusted EPS increased to $2.31 from $2.09. The company raised its full-year guidance, forecasting adjusted revenue of $4.9 billion and EPS of $10.81. Key segments, Diagnostics and Discovery & Analytical Solutions, both saw significant revenue increases, contributing to a strong financial outlook.
PerkinElmer, Inc. (NYSE: PKI) has released its 2021 Corporate Social Responsibility (CSR) Report, detailing its progress in environmental, social, and governance (ESG) initiatives. The report highlights a 8.5% reduction in Scope 1 and 2 emissions, a 15% decrease in hazardous waste, and increased female representation in leadership roles to 31%. Four new commitments were announced, targeting carbon neutrality by 2040, waste reduction by 2025, and enhancing female leadership. The company aims to maintain transparency in its ESG goals under SASB guidelines.
The Board of Directors of PerkinElmer (NYSE: PKI) has declared a quarterly dividend of
PerkinElmer (NYSE: PKI) and Honeycomb Biotechnologies have launched the innovative HIVETM scRNAseq Solution, designed for single-cell isolation and analysis. This portable device allows the capture, storage, and RNA sequencing of fragile cell types without the need for specialized equipment, enhancing research opportunities. The HIVE solution maintains sample integrity, improving workflow efficiency for multi-site studies. This technology aims to drive advancements in diagnostics and therapeutic development, particularly for academic collaborations and clinical trials.
PerkinElmer, Inc. (NYSE: PKI) announced it will release its third quarter 2021 financial results on November 2, 2021, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results, featuring CEO Prahlad Singh and CFO Jamey Mock. Investors can access a live audio webcast via the company’s website. A replay of the call will be available after 7:00 p.m. ET on the same day. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and aims to innovate for a healthier world.
PerkinElmer, NYSE:PKI, has received Emergency Use Authorization (EUA) from the FDA for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1. This test allows labs to simultaneously detect and differentiate between SARS-CoV-2, influenza A, influenza B, and RSV from respiratory samples. The test aims to streamline testing during the flu season, helping to alleviate confusion from similar symptoms. PerkinElmer's existing CE marking for this test in over 30 countries is also noted. The company reported revenues of approximately $3.8 billion in 2020.
PerkinElmer has received Emergency Use Authorization (EUA) from the U.S. FDA for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG). This assay enables the qualitative and semi-quantitative detection of IgG antibodies against the SARS-CoV-2 S1 antigen in human serum and plasma. It is designed for use by CLIA-certified laboratories and plays a critical role in vaccine development and research on immunity. The assay can be used manually or on various ELISA platforms, enhancing laboratory capabilities in understanding COVID-19 immunity.
PerkinElmer, Inc. (NYSE: PKI) has successfully completed its acquisition of BioLegend for approximately $5.25 billion. This strategic move represents the largest acquisition in PerkinElmer's history, expanding its life science offerings into high-growth sectors such as cytometry and proteogenomics. BioLegend is projected to enhance PerkinElmer's revenue by $380 million and contribute $0.30 to adjusted earnings per share in fiscal year 2022. The integration aims to bolster innovation in therapeutic discovery and improve the overall reagents portfolio.
PerkinElmer (NYSE: PKI) announced the pricing of a total of
FAQ
What is the market cap of PERKINELMER (PKI)?
What core markets does PerkinElmer Inc. serve?
How does PerkinElmer generate its revenue?
What distinguishes PerkinElmer from its competitors?
How does PerkinElmer contribute to advancements in healthcare and research?
What is the significance of PerkinElmer's focus on innovation?
In which regions does PerkinElmer operate?
How does PerkinElmer support its customer base?
What industry-specific expertise does PerkinElmer offer?
